Navigation Links
Solution to bacterial mystery promises new drugs

A 25-year quest to identify the first biochemical step that many disease-causing bacteria use to build their membranes has led to a discovery that holds promise for effective, new antibiotics against these bacteria, according to investigators at St. Jude Children's Research Hospital. The finding is significant because the biochemical step the antibiotic would block is not used by humans. Therefore, such a drug would not cause dangerous side effects.

A report on this finding appears in the September 1 issue of Molecular Cell.

The discovery also demonstrated that current textbooks use the wrong type of bacterium as a model to explain a critical biochemical step that most disease-causing bacteria use to make their membranes, according to Charles Rock, Ph.D., a member of the St. Jude Department of Infectious Diseases and senior author of the paper. As bacteria grow in size or divide, they must make additional membrane using a series of biochemical reactions. The first step in this process is the transfer of a fatty acid to a molecule called G3P. Bacteria then convert this molecule into a variety of other molecules called phospholipids, which are the building blocks of membranes.

"We identified a biochemical process that uses a previously unrecognized molecule as a raw material to make phospholipid," Rock said. "That discovery solved a mystery that has puzzled researchers for 25 years."

Scientists have used E. coli bacteria for many years as a model to understand how disease-causing bacteria make membrane phospholipids, but E. coli is an unsuitable model for most pathogens (disease-causing bacteria), according to Rock.

First, E. coli is a so-called gram-negative bacterium, while many of the pathogens researchers are interested in are gram-positive, Rock noted. Among those gram-positive organisms are Staphylococcus aureus, which causes skin infections and serious blood infections, and Streptococcus pneumoniae, which causes pneu
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Solution to Pollution: New Bacteria Eats Toxic Waste
3. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
4. Solution to legionella
5. Anti-bacterial additive widespread in U.S. waterways
6. A bacterial genome reveals new targets to combat infectious disease
7. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
8. Scientists discover that host cell lipids facilitate bacterial movement
9. Protein prevents detrimental immune effects of bacterial sepsis
10. Researchers develop new method for facile identification of proteins in bacterial cells
11. A virus-like hitchhiker may trigger bacterial meningitis

Post Your Comments:
(Date:11/9/2009)...9, 2009 / b3c newswire / - Today, TNO, a Dutch ...an American organization for contract research and...ned a letter of intent with regard to TNOs dynamic...r of intent proposes a collaboration in which Seve...lization in North America. The TIM systems will be...
(Date:11/9/2009)...stry leaders from around the world will gather in ...lecular Targets and Cancer Therapeutics Internatio...information on important cancer therapies in devel...reat it effectively we need a greater understandin...r level," said Lewis Cantley, Ph.D., director of t...
(Date:11/8/2009)...hers at Purdue University have discovered a new ap...l cord injuries using nano-spheres that could be i..., The synthetic "copolymer micelles" are drug-de... roughly 100 times smaller than the diameter of a ... how to deliver drugs for cancer treatment and oth...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 1InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 1NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 3Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 1Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 2
... When Yadong Wang, a chemist by training, first ve...idn,t know that his peers would have considered hi...cuits use electrical signals often conducted by ne...te between the brain and the rest of the body, he ...ed to repair a broken circuit. The neurotransmitte...
... University of Manchester researchers are recruiti...?commonly known as sciatica ?in the first ever stu...their condition. , Dr Christopher McCarthy and his...n Science need 30 volunteers aged 22-55 who have h...nt and have not had previous spinal surgery. , ...
... Using the latest in high tech tools, researchers ...edictive of chronic lung rejection up to 20 months...patients have the highest mortality rate of organ ...nvestigator and pulmonologist Chris Wendt. Current...splants will fail, and when signs of chronic rejec...
Other Biology News:Dopamine used to prompt nerve tissue to regrow 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
(Date:11/6/2009)...Newswire-FirstCall/ -- Helix BioPharma Corp. (TSX,...that John Docherty, president and chief operating ...h annual Investor Summit on November 10, 2009 at 4... Docherty will provide an overview of the Company,... Topical Interferon Alpha-2b. The slide show port...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- ,, 3Q09 Corporate H...TM) E.U. Marketing Authorization to Astellas Pharm...rcial readiness activities Expanded management te...; and Director, Commercial Operations Appointed B...Committee chairman , Upcoming 2009 Mileston...
(Date:11/6/2009)...Newswire/ -- Intarcia Therapeutics, Inc. delivered...74; continuous delivery of exenatide) program for ...al Diabetes Technology Meeting in San Francisco, C...nh/20050301/SFTU126LOGO ) ,, Continuous Subcu...Plasma Glucose, HbA1c and Reduces Weight in a 28-d...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...RDAM, The Netherlands, February 18 ,Amsterdam Mole...e field of,human gene therapy, announced today tha...ll year 2008 on Tuesday, February 24, 2009 at 7:00...results, the Company will,conduct a conference cal... for the Netherlands is 0800-949-4166 (toll free)....
...b., Feb. 18 Transgenomic Inc. (OTC Bulletin Board...hat: Transgenomic Inc. Fourth Quarter 2008 Ear...en: Wednesday, February 25, 2009 @ 5:00 p.m. E...vents.asp?id=6 , How: Live over the Intern... address above., , , To access the call via te...
...ES, Feb. 18 The Board of Directors wishes to conf...y 4, 2009 it resolved to file a Form 15 with effec...t require the approval of stockholders but in the ...olders informed the Board is making this Release. ...ompany from its United States Securities and Excha...
Other Biology Technology:AMT to Release Full Year 2008 Results on February 24, 2009 2Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4
SILVER SEQUENCE Staining Reagents from Promega
Sheep Anti-Decorin Polyclonal Antibody, Unconjugated from Abcam
Mouse Complement from Equitech-Bio
...S-4P, all Programmable and Digital Orbital Shaker.... been redesigned to make every day use even easier...memory for up to 4 different programs. Its easy re...am. Furthermore, the VSOS-4P has a pulse operation...
Biology Products: